-
【2022 ESMO】Breaking the cocoon into a butterfly, born to the new Professor Wang Zhijie: EGFR ex20ins non-small cell lung cancer treatment field adds a new evidence
Time of Update: 2022-10-03
Among them, the data received by Amivantamab (AMI group) were from the CHRYSALIS study; Data for the RW treatment regimen (external control group) are from the Japanese cohort of EGFR ex20ins mutations in advanced NSCLC who received docetaxel (DOC)/tyrosine kinase inhibitor (TKI)/immunotherapy (IO) for the first time after platinum chemotherapy failure screened by the Asian Lung Cancer Genome Monitoring Platform (LC-SCRUM-Asia).
-
Express The world's first batch! The first EZH1/2 dual inhibitor is approved to treat blood cancers
Time of Update: 2022-09-30
Retrieved September 27, 2022 from Recently, Daiichi Sankyo announced that its drug Ezharmia (valemetostat tosilate) has been approved by Japan's Ministry of Health, Labor and Welfare (MHLW) for the treatment of relapsed/refractory (r/r) adult T-cell lymphoma (ATL).
-
Fosun Pharma was the first to reduce its holdings, but the pharmaceutical business grew against the trend, can it revitalize its glory in the future
Time of Update: 2022-09-20
This is fosun pharma's third largest equity acquisition transaction in the past 10 years, in 2020 and 2021, BioNTech stock price increased by 140% and 216% respectively due to the new crown epidemic, and as of the end of 2021, this investment has brought more than 2.
-
Rehwald's Stroke Research Lecture Series 3 Highlights Replay
Time of Update: 2022-08-30
In 2022, Raywald's "Dacheng Academy | Stroke Research Series Lectures" has launched three live broadcast courses in a row, covering stroke mechanism exploration, model building, treatment and other as
-
Nat Commun: Transient viral exposure drives humoral immune responses in HIV-1 post-treatment controllers
Time of Update: 2022-05-16
The results of the study were published in the journal Nature Communications on April 11, 2022, with the title "Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers" .
Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers2.
-
A&R: 2021 American College of Rheumatology Guidelines for the Treatment of Juvenile Idiopathic Arthritis: Management of Oligoarthritis, TMJ Arthritis, and Systemic Juvenile Idiopathic Arthritis
Time of Update: 2022-05-14
Although the quality of evidence is generally low and many recommendations are conditional, including caregivers and patients in the decision-making process enhances the relevance and applicability of guidelines .
-
Lancet Haematol: All-trans retinoic acid increased dose dexamethasone can be used as the first-line treatment for patients with newly diagnosed immune thrombocytopenia
Time of Update: 2022-01-08
Recently, a multicenter, open-label, randomized, controlled, phase 2 trial was published in the journal Lancet Haematol, aiming to evaluate all-trans retinoic acid with increased dose dexamethasone as the first-line treatment for patients with newly diagnosed immune thrombocytopenia The activity and safety .
-
Teriplizumab has a new indication, osimertinib + bevacizumab failed to bring benefits to drug-resistant patients
Time of Update: 2021-12-05
(If you need the original text of the literature, you can add the editor WeChat yxj_oncology to obtain it) Key points: Annals of Oncology: Osimertinib combined with bevacizumab failed to give epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) ) Treatment failure patients bring survival benefits NEJM: Hypoxia-inducible factor-2α (HIF-2α) inhibitor Belzutifan in the treatment of Von Hippel-Lindau (VHL) syndrome-associated renal cell carcinoma (RCC) has a gratifying effect.
-
Non-athletes can also get traumatic brain injury
Time of Update: 2021-02-25
Finally, they collected some medical records and looked under a microscope for tissue in three parts of each brain for CTE symptoms.
People who engage in contact exercise are more likely to develop CTE symptoms.
-
There is another class of new drugs declared in the tablets eager to seize the hepatitis drug market
Time of Update: 2020-09-01
On August 18th, the pharmaceutical network announced that a class of 1 new drug PZH2109 capsules declared clinically received CDE acceptance, the drug is mainly used to treat non-alcoholic fatty hepatitis, the United States and China have no same target of the same adaptive drugs approved for market.
-
AXS-05 Treatment of Alzheimer's Disease-Related Intensive Phase II/III Trial Accelerated
Time of Update: 2020-05-31
Alzheimer's disease (AD) is a progressive neurodegenerative disease that initially manifests itself as forgetfulness and then develops into severe cognitive impairment and memory loss It is estimated
-
Symptoms of chorea
Time of Update: 2020-04-03
Chorea is a general term for a series of diseases, which can lead to unconsciousness and contraction of different parts of the body The disease is usually named after the place where the body moves Hu
